The attack took the lives of four Polish citizens, a British national, and an Austrian woman, while two police officers were among the fifteen injured. Investigators subsequently found the bodies of the gunman's parents and sister at his residence, though officials emphasize that the inquiry into his motives remains active. Harry Marchant, the 19-year-old wounded in the incident, remains in stable condition receiving hospital care as his family thanked local emergency personnel.
Key points
Harry Marchant remains in stable condition in the hospital after receiving treatment for…: Harry Marchant remains in stable condition in the hospital after receiving treatment for his gunshot wounds.
Polish prosecutors continue to investigate the motive despite early suggestions that the…: Polish prosecutors continue to investigate the motive despite early suggestions that the attacker was influenced by far-right ideology.
British tourists sheltered in nearby businesses during the gunfire and prepared to return…: British tourists sheltered in nearby businesses during the gunfire and prepared to return to the United Kingdom.
Sources checked by our analysis pipeline: 1
- Published
A 19-year-old British man is in a stable condition after being shot by a gunman in Krakow, Poland.
Harry Marchant, from York, suffered a gunshot wound in the attack on Saturday, which began shortly before 15:00 local time (14:00 GMT) in Krakow's busy Main Market Square.
The 24-year-old attacker, who died in hospital on Monday, fatally shot four Polish citizens, a British national and an Austrian woman, while a further 15 people, including two police officers, were injured.
Marchant's family said he was receiving ongoing hospital treatment for his injuries.
"We can't express how grateful we are to the first responders, medical team, and the people of Poland for their help and care for Harry," they added.
"We ask for our privacy to be respected as we support Harry with his recovery."
Twin sisters Sienna and Rimini Chapman were also in Krakow at the time of the incident and said they "ran for our lives" when they heard shots.
The 20-year-olds, from Northallerton, North Yorkshire, were part of a group celebrating a friend's 21st birthday in Poland when…
Food and Drug Administration has issued a warning that GLP-1 drugs may pose a risk of a rare condition that causes vision loss. While the risk appears to be small and current data remains mixed, the agency wants patients to be aware of the potential complication.
Regulatory scrutiny is expanding across widely prescribed metabolic treatments alongside significant clinical advances in genetic medicine. Biotechnology developers are moving forward with key trial milestones for severe inherited disorders, including gene-edited therapies approaching potential commercial review. These parallel events highlight both ongoing drug safety surveillance and therapeutic momentum across modern pharmaceutical pipelines.
Federal regulators have cleared Bayer's novel therapy Sunharbo to prevent recurrent strokes without triggering the severe bleeding risks associated with traditional blood thinners. Concurrently, the agency issued an official warning alerting patients and physicians that popular GLP-1 treatments may cause a rare condition that leads to sudden vision loss. These actions address critical gaps in secondary stroke management while establishing new safety protocols for widely prescribed metabolic medications.